| May 1, 2026 |
AZN |
6-K filed: Foreign issuer report |
Filing |
— |
| May 1, 2026 |
AZN |
6-K filed: Clinical or regulatory announcement |
Filing |
— |
| May 1, 2026 |
AZN |
6-K filed: Clinical or regulatory announcement |
Filing |
— |
| May 1, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| May 1, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| May 1, 2026 |
BIIB |
A Study to Learn How the Body Processes BIIB141 (Omaveloxolone) When Taken as a Capsule or as a Tablet Dissolved in Liquid, and to Learn About Its Safety in Healthy Adults Ages 18 to 55 |
Trial Milestone |
Phase 1 |
| May 1, 2026 |
BNTX |
A Study to Learn About COVID-19 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 in Participants Ages 12 Through 64 Years Considered at Higher Risk of Severe COVID-19, and Participants Ages ≥65 Years |
Trial Milestone |
Phase 3 |
| May 1, 2026 |
AAPG |
6-K filed: Foreign issuer report |
Filing |
— |
| May 1, 2026 |
MRNA |
Quarterly results filed (8-K) |
Earnings |
— |
| May 1, 2026 |
ACAD |
8-K filed: Leadership change, Reg FD disclosure |
Corporate |
— |
| May 1, 2026 |
MANE |
8-K filed: Material agreement |
Corporate |
— |
| May 1, 2026 |
LNTH |
8-K filed: Leadership change |
Corporate |
— |
| May 1, 2026 |
OLMA |
8-K filed: Material agreement |
Corporate |
— |
| May 1, 2026 |
NRIX |
A Single and Multiple Ascending Doses, Relative Bioavailability, Food Effect, and Drug-Drug Interaction Study of NX-5948 in Healthy Volunteers |
Trial Milestone |
Phase 1 |
| May 1, 2026 |
TLSA |
Results filed (20-F) |
Earnings |
— |
| May 1, 2026 |
PTCHF |
6-K filed: Foreign issuer report |
Filing |
— |
| May 1, 2026 |
KNSA |
8-K filed: Leadership change |
Corporate |
— |
| May 1, 2026 |
RADX |
6-K filed: Foreign issuer report |
Filing |
— |
| May 1, 2026 |
ALDX |
8-K filed: Reg FD disclosure |
Filing |
— |
| May 1, 2026 |
CRIS |
8-K filed: Listing / standard notice |
Corporate |
— |
| May 2, 2026 |
REGN |
Study of Bet v1 Antibodies Effect on Eye Allergy Symptoms in Adolescents and Adults With Birch Pollen Allergy |
Trial Milestone |
Phase 3 |
| May 4, 2026 |
BMRN |
Quarterly results filed (8-K) |
Earnings |
— |
| May 4, 2026 |
AXSM |
Quarterly results filed (8-K) |
Earnings |
— |
| May 4, 2026 |
MIRM |
8-K filed: Other event |
Filing |
— |
| May 4, 2026 |
NUVB |
Quarterly results filed (8-K) |
Earnings |
— |
| May 4, 2026 |
OCGN |
Quarterly results filed (8-K) |
Earnings |
— |
| May 4, 2026 |
CABA |
Quarterly results filed (8-K) |
Earnings |
— |
| May 4, 2026 |
CABA |
8-K filed: Other event |
Filing |
— |
| May 4, 2026 |
VTRS |
8-K filed: Leadership change, Reg FD disclosure |
Corporate |
— |
| May 4, 2026 |
TVTX |
Quarterly results filed (8-K) |
Earnings |
— |
| May 4, 2026 |
GKOS |
8-K filed: Reg FD disclosure |
Filing |
— |
| May 4, 2026 |
IMNN |
8-K filed: Leadership change |
Corporate |
— |
| May 4, 2026 |
PRQR |
6-K filed: Foreign issuer report |
Filing |
— |
| May 4, 2026 |
ORIC |
Quarterly results filed (8-K) |
Earnings |
— |
| May 4, 2026 |
AURA |
Quarterly results filed (8-K) |
Earnings |
— |
| May 4, 2026 |
AURA |
8-K filed: Leadership change, Reg FD disclosure, Other event |
Corporate |
— |
| May 4, 2026 |
KYTX |
8-K filed: Other event |
Filing |
— |
| May 4, 2026 |
CRSP |
Quarterly results filed (8-K) |
Earnings |
— |
| May 4, 2026 |
ONCY |
8-K filed: Other event |
Filing |
— |
| May 4, 2026 |
COAG |
8-K filed: Other event |
Filing |
— |
| May 4, 2026 |
CATX |
Quarterly results filed (8-K) |
Earnings |
— |
| May 4, 2026 |
BCRX |
8-K filed: Reg FD disclosure |
Filing |
— |
| May 4, 2026 |
VRTX |
Quarterly results filed (8-K) |
Earnings |
— |
| May 4, 2026 |
CLLS |
6-K filed: Foreign issuer report |
Filing |
— |
| May 5, 2026 |
PFE |
Quarterly results filed (8-K) |
Earnings |
— |
| May 5, 2026 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| May 5, 2026 |
SNY |
6-K filed: Foreign issuer report |
Filing |
— |
| May 5, 2026 |
NVO |
6-K filed: Foreign issuer report |
Filing |
— |
| May 5, 2026 |
BNTX |
6-K filed: Foreign issuer report |
Filing |
— |
| May 5, 2026 |
BNTX |
6-K filed: Foreign issuer report |
Filing |
— |
| May 5, 2026 |
NBIX |
Quarterly results filed (8-K) |
Earnings |
— |
| May 5, 2026 |
EXEL |
Quarterly results filed (8-K) |
Earnings |
— |
| May 5, 2026 |
RARE |
Quarterly results filed (8-K) |
Earnings |
— |
| May 5, 2026 |
JAZZ |
Quarterly results filed (8-K) |
Earnings |
— |
| May 5, 2026 |
ALKS |
Quarterly results filed (8-K) |
Earnings |
— |
| May 5, 2026 |
OCUL |
Quarterly results filed (8-K) |
Earnings |
— |
| May 5, 2026 |
IDYA |
8-K filed: Other event |
Filing |
— |
| May 5, 2026 |
IDYA |
Quarterly results filed (8-K) |
Earnings |
— |
| May 5, 2026 |
OCGN |
Quarterly results filed (8-K) |
Earnings |
— |
| May 5, 2026 |
CYTK |
8-K filed: Other event |
Filing |
— |
| May 5, 2026 |
CYTK |
Quarterly results filed (8-K) |
Earnings |
— |
| May 5, 2026 |
RYTM |
Quarterly results filed (8-K) |
Earnings |
— |
| May 5, 2026 |
DNTH |
Quarterly results filed (8-K) |
Earnings |
— |
| May 5, 2026 |
SUPN |
Quarterly results filed (8-K) |
Earnings |
— |
| May 5, 2026 |
RCUS |
Quarterly results filed (8-K) |
Earnings |
— |
| May 5, 2026 |
TRVI |
Quarterly results filed (8-K) |
Earnings |
— |
| May 5, 2026 |
COGT |
Quarterly results filed (8-K) |
Earnings |
— |
| May 5, 2026 |
PTGX |
Quarterly results filed (8-K) |
Earnings |
— |
| May 5, 2026 |
QURE |
Quarterly results filed (8-K) |
Earnings |
— |
| May 5, 2026 |
OTLC |
8-K filed: Material agreement, Acquisition completed |
Corporate |
— |
| May 5, 2026 |
RLAY |
Quarterly results filed (8-K) |
Earnings |
— |
| May 5, 2026 |
AURA |
8-K filed: Material agreement |
Corporate |
— |
| May 5, 2026 |
CLYM |
8-K filed: Reg FD disclosure |
Filing |
— |
| May 5, 2026 |
SYRE |
Quarterly results filed (8-K) |
Earnings |
— |
| May 5, 2026 |
VALN |
6-K filed: Foreign issuer report |
Filing |
— |
| May 5, 2026 |
NERV |
Quarterly results filed (8-K) |
Earnings |
— |
| May 5, 2026 |
IRON |
Quarterly results filed (8-K) |
Earnings |
— |
| May 5, 2026 |
EDIT |
Quarterly results filed (8-K) |
Earnings |
— |
| May 5, 2026 |
XNCR |
8-K filed: Reg FD disclosure |
Filing |
— |
| May 5, 2026 |
QTTB |
Quarterly results filed (8-K) |
Earnings |
— |
| May 5, 2026 |
RIGL |
Quarterly results filed (8-K) |
Earnings |
— |
| May 6, 2026 |
GSK |
Results filed (6-K) |
Earnings |
— |
| May 6, 2026 |
REGN |
Study of Natriuretic Peptide Receptor 1 (NPR1) Antagonist in Adult Patients With Postural Orthostatic Tachycardia Syndrome (POTS) |
Trial Milestone |
Phase 2 |
| May 6, 2026 |
NVO |
6-K filed: Foreign issuer report |
Filing |
— |
| May 6, 2026 |
GILD |
Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) |
Trial Milestone |
Phase 3 |
| May 6, 2026 |
ARGX |
6-K filed: Foreign issuer report |
Filing |
— |
| May 6, 2026 |
ONC |
Quarterly results filed (8-K) |
Earnings |
— |
| May 6, 2026 |
VNDA |
Quarterly results filed (8-K) |
Earnings |
— |
| May 6, 2026 |
RVMD |
Quarterly results filed (8-K) |
Earnings |
— |
| May 6, 2026 |
MIRM |
Quarterly results filed (8-K) |
Earnings |
— |
| May 6, 2026 |
TGTX |
Quarterly results filed (8-K) |
Earnings |
— |
| May 6, 2026 |
TSHA |
Quarterly results filed (8-K) |
Earnings |
— |
| May 6, 2026 |
EYPT |
Quarterly results filed (8-K) |
Earnings |
— |
| May 6, 2026 |
ACAD |
Quarterly results filed (8-K) |
Earnings |
— |
| May 6, 2026 |
MDGL |
Quarterly results filed (8-K) |
Earnings |
— |
| May 6, 2026 |
CLDX |
A Study of Barzolvolimab in Patients With Atopic Dermatitis |
Trial Milestone |
Phase 2 |
| May 6, 2026 |
PCVX |
Quarterly results filed (8-K) |
Earnings |
— |
| May 6, 2026 |
VIR |
Quarterly results filed (8-K) |
Earnings |
— |
| May 6, 2026 |
SRPT |
Quarterly results filed (8-K) |
Earnings |
— |
| May 6, 2026 |
URGN |
Quarterly results filed (8-K) |
Earnings |
— |
| May 6, 2026 |
IMCR |
Quarterly results filed (8-K) |
Earnings |
— |
| May 6, 2026 |
MDWD |
6-K filed: Foreign issuer report |
Filing |
— |
| May 6, 2026 |
UTHR |
Quarterly results filed (8-K) |
Earnings |
— |
| May 6, 2026 |
LYEL |
Quarterly results filed (8-K) |
Earnings |
— |
| May 6, 2026 |
RXRX |
Quarterly results filed (8-K) |
Earnings |
— |
| May 6, 2026 |
BCRX |
Quarterly results filed (8-K) |
Earnings |
— |
| May 6, 2026 |
DMAC |
Quarterly results filed (8-K) |
Earnings |
— |
| May 6, 2026 |
MLYS |
Quarterly results filed (8-K) |
Earnings |
— |
| May 6, 2026 |
BTMD |
Quarterly results filed (8-K) |
Earnings |
— |
| May 6, 2026 |
LXRX |
8-K filed: Material agreement, Reg FD disclosure |
Corporate |
— |
| May 6, 2026 |
LKFT |
6-K filed: Foreign issuer report |
Filing |
— |
| May 6, 2026 |
TPST |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| May 6, 2026 |
TCRX |
Quarterly results filed (8-K) |
Earnings |
— |
| May 6, 2026 |
MNKD |
Quarterly results filed (8-K) |
Earnings |
— |
| May 6, 2026 |
ACTU |
8-K filed: Leadership change, Other event |
Corporate |
— |
| May 6, 2026 |
XNCR |
Quarterly results filed (8-K) |
Earnings |
— |
| May 7, 2026 |
ABBV |
An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer |
Trial Milestone |
Phase 1 |
| May 7, 2026 |
GILD |
Quarterly results filed (8-K) |
Earnings |
— |
| May 7, 2026 |
ARGX |
6-K filed: Foreign issuer report |
Filing |
— |
| May 7, 2026 |
SVA |
6-K filed: Foreign issuer report |
Filing |
— |
| May 7, 2026 |
BNTX |
6-K filed: Foreign issuer report |
Filing |
— |
| May 7, 2026 |
IBRX |
Quarterly results filed (8-K) |
Earnings |
— |
| May 7, 2026 |
ARWR |
Quarterly results filed (8-K) |
Earnings |
— |
| May 7, 2026 |
PRAX |
Quarterly results filed (8-K) |
Earnings |
— |
| May 7, 2026 |
XENE |
Quarterly results filed (8-K) |
Earnings |
— |
| May 7, 2026 |
INSM |
Quarterly results filed (8-K) |
Earnings |
— |
| May 7, 2026 |
FDMT |
Quarterly results filed (8-K) |
Earnings |
— |
| May 7, 2026 |
DFTX |
Quarterly results filed (8-K) |
Earnings |
— |
| May 7, 2026 |
QNRX |
Quarterly results filed (8-K) |
Earnings |
— |
| May 7, 2026 |
VSTM |
8-K filed: Reg FD disclosure |
Filing |
— |
| May 7, 2026 |
KOD |
Quarterly results filed (8-K) |
Earnings |
— |
| May 7, 2026 |
GRFS |
6-K filed: Foreign issuer report |
Filing |
— |
| May 7, 2026 |
OCGN |
Quarterly results filed (8-K) |
Earnings |
— |
| May 7, 2026 |
CLDX |
Quarterly results filed (8-K) |
Earnings |
— |
| May 7, 2026 |
ASND |
6-K filed: Foreign issuer report |
Filing |
— |
| May 7, 2026 |
ASND |
6-K filed: Foreign issuer report |
Filing |
— |
| May 7, 2026 |
IOVA |
Quarterly results filed (8-K) |
Earnings |
— |
| May 7, 2026 |
PHAR |
6-K filed: Foreign issuer report |
Filing |
— |
| May 7, 2026 |
PHAR |
6-K filed: Foreign issuer report |
Filing |
— |
| May 7, 2026 |
VTRS |
Quarterly results filed (8-K) |
Earnings |
— |
| May 7, 2026 |
ANNX |
Quarterly results filed (8-K) |
Earnings |
— |
| May 7, 2026 |
RAPP |
Quarterly results filed (8-K) |
Earnings |
— |
| May 7, 2026 |
PVLA |
Quarterly results filed (8-K) |
Earnings |
— |
| May 7, 2026 |
LNTH |
Quarterly results filed (8-K) |
Earnings |
— |
| May 7, 2026 |
DNLI |
Quarterly results filed (8-K) |
Earnings |
— |
| May 7, 2026 |
NKTR |
Quarterly results filed (8-K) |
Earnings |
— |
| May 7, 2026 |
GENB |
Quarterly results filed (8-K) |
Earnings |
— |
| May 7, 2026 |
VCEL |
Quarterly results filed (8-K) |
Earnings |
— |
| May 7, 2026 |
DCTH |
Quarterly results filed (8-K) |
Earnings |
— |
| May 7, 2026 |
ABVX |
6-K filed: Foreign issuer report |
Filing |
— |
| May 7, 2026 |
VERA |
Quarterly results filed (8-K) |
Earnings |
— |
| May 7, 2026 |
SRRK |
Quarterly results filed (8-K) |
Earnings |
— |
| May 7, 2026 |
AMLX |
Quarterly results filed (8-K) |
Earnings |
— |
| May 7, 2026 |
EWTX |
Quarterly results filed (8-K) |
Earnings |
— |
| May 7, 2026 |
MBX |
Quarterly results filed (8-K) |
Earnings |
— |
| May 7, 2026 |
BEAM |
Quarterly results filed (8-K) |
Earnings |
— |
| May 7, 2026 |
STOK |
Quarterly results filed (8-K) |
Earnings |
— |
| May 7, 2026 |
CAPR |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| May 7, 2026 |
CRVS |
Quarterly results filed (8-K) |
Earnings |
— |
| May 7, 2026 |
LONA |
Quarterly results filed (8-K) |
Earnings |
— |
| May 7, 2026 |
INTS |
Quarterly results filed (8-K) |
Earnings |
— |
| May 7, 2026 |
CLYM |
Quarterly results filed (8-K) |
Earnings |
— |
| May 7, 2026 |
PBYI |
Quarterly results filed (8-K) |
Earnings |
— |
| May 7, 2026 |
LXRX |
Quarterly results filed (8-K) |
Earnings |
— |
| May 7, 2026 |
AMRX |
Quarterly results filed (8-K) |
Earnings |
— |
| May 7, 2026 |
TRDA |
Quarterly results filed (8-K) |
Earnings |
— |
| May 7, 2026 |
LPCN |
8-K filed: Other event |
Filing |
— |
| May 7, 2026 |
LPCN |
Quarterly results filed (8-K) |
Earnings |
— |
| May 7, 2026 |
CRDL |
6-K filed: Foreign issuer report |
Filing |
— |
| May 7, 2026 |
AKBA |
Quarterly results filed (8-K) |
Earnings |
— |
| May 7, 2026 |
CGEM |
Quarterly results filed (8-K) |
Earnings |
— |
| May 7, 2026 |
BDTX |
Quarterly results filed (8-K) |
Earnings |
— |
| May 8, 2026 |
NVO |
A Research Study Looking at How Food Intake Affects Inno8 in the Body of Healthy People |
Trial Milestone |
Phase 1 |
| May 8, 2026 |
SVA |
6-K filed: Foreign issuer report |
Filing |
— |
| May 8, 2026 |
CYTK |
8-K filed: Other event |
Filing |
— |
| May 8, 2026 |
VTGN |
8-K filed: Other event |
Filing |
— |
| May 8, 2026 |
HUMA |
8-K filed: Listing / standard notice |
Corporate |
— |
| May 8, 2026 |
NKTR |
8-K filed: Material agreement, Leadership change |
Corporate |
— |
| May 8, 2026 |
CGON |
Quarterly results filed (8-K) |
Earnings |
— |
| May 8, 2026 |
ALXO |
Quarterly results filed (8-K) |
Earnings |
— |
| May 8, 2026 |
TNGX |
8-K filed: Leadership change |
Corporate |
— |
| May 8, 2026 |
CLRB |
8-K filed: Material agreement, Other event |
Corporate |
— |
| May 8, 2026 |
MBRX |
8-K filed: Reg FD disclosure |
Filing |
— |
| May 8, 2026 |
TMCI |
Quarterly results filed (8-K) |
Earnings |
— |
| May 8, 2026 |
KPRX |
Quarterly results filed (8-K) |
Earnings |
— |
| May 8, 2026 |
BIOA |
Quarterly results filed (8-K) |
Earnings |
— |
| May 11, 2026 |
AZN |
A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone |
Trial Milestone |
Phase 2 |
| May 11, 2026 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| May 11, 2026 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| May 11, 2026 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| May 11, 2026 |
GILD |
Study of GS-0272 in Participants With Rheumatoid Arthritis |
Trial Milestone |
Phase 1 |
| May 11, 2026 |
INCY |
A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib |
Trial Milestone |
Phase 2 |
| May 11, 2026 |
ARGX |
6-K filed: Foreign issuer report |
Filing |
— |
| May 11, 2026 |
NTLA |
Quarterly results filed (8-K) |
Earnings |
— |
| May 11, 2026 |
EIKN |
Quarterly results filed (8-K) |
Earnings |
— |
| May 11, 2026 |
LQDA |
Quarterly results filed (8-K) |
Earnings |
— |
| May 11, 2026 |
MLTX |
Quarterly results filed (8-K) |
Earnings |
— |
| May 11, 2026 |
TVTX |
8-K filed: Material agreement, Other event |
Corporate |
— |
| May 11, 2026 |
DYN |
Quarterly results filed (8-K) |
Earnings |
— |
| May 11, 2026 |
TRVI |
A Food Effect Study to Evaluate the Relative Bioavailability of Nalbuphine Extended-Release Tablets (NAL ER) in Healthy Participants |
Trial Milestone |
Phase 1 |
| May 11, 2026 |
OCS |
6-K filed: Foreign issuer report |
Filing |
— |
| May 11, 2026 |
AVBP |
8-K filed: Other event |
Filing |
— |
| May 11, 2026 |
AVBP |
Quarterly results filed (8-K) |
Earnings |
— |
| May 11, 2026 |
PHVS |
6-K filed: Foreign issuer report |
Filing |
— |
| May 11, 2026 |
MBX |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| May 11, 2026 |
BCAX |
Quarterly results filed (8-K) |
Earnings |
— |
| May 11, 2026 |
AURA |
Quarterly results filed (8-K) |
Earnings |
— |
| May 11, 2026 |
KYNB |
Quarterly results filed (8-K) |
Earnings |
— |
| May 11, 2026 |
LXEO |
Quarterly results filed (8-K) |
Earnings |
— |
| May 11, 2026 |
COAG |
8-K filed: Leadership change |
Corporate |
— |
| May 11, 2026 |
CATX |
Quarterly results filed (8-K) |
Earnings |
— |
| May 11, 2026 |
TTRX |
Quarterly results filed (8-K) |
Earnings |
— |
| May 11, 2026 |
HALO |
Quarterly results filed (8-K) |
Earnings |
— |
| May 11, 2026 |
ERAS |
Quarterly results filed (8-K) |
Earnings |
— |
| May 11, 2026 |
CRDL |
6-K filed: Foreign issuer report |
Filing |
— |
| May 11, 2026 |
ACTU |
8-K filed: Reg FD disclosure |
Filing |
— |
| May 11, 2026 |
AGEN |
Quarterly results filed (8-K) |
Earnings |
— |
| May 11, 2026 |
CLLS |
6-K filed: Foreign issuer report |
Filing |
— |
| May 11, 2026 |
CLLS |
6-K filed: Foreign issuer report |
Filing |
— |
| May 11, 2026 |
WST |
8-K filed: Reg FD disclosure |
Filing |
— |
| May 12, 2026 |
NVS |
A First-in-human, Proof of Concept Study of CPK850 in Patients With RLBP1 Retinitis Pigmentosa |
Trial Milestone |
Phase 1/Phase 2 |
| May 12, 2026 |
PFE |
A Study to Learn About the Safety and Immune Response of a New Pneumococcal Vaccine in Adults |
Trial Milestone |
Phase 1/Phase 2 |
| May 12, 2026 |
AGIO |
A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD) |
Trial Milestone |
Phase 2 |
| May 12, 2026 |
AAPG |
6-K filed: Foreign issuer report |
Filing |
— |
| May 12, 2026 |
MRNA |
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age |
Trial Milestone |
Phase 1/Phase 2 |
| May 12, 2026 |
ALKS |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| May 12, 2026 |
DFTX |
8-K filed: Other event |
Filing |
— |
| May 12, 2026 |
MANE |
Quarterly results filed (8-K) |
Earnings |
— |
| May 12, 2026 |
VRCA |
Quarterly results filed (8-K) |
Earnings |
— |
| May 12, 2026 |
VTGN |
8-K filed: Other event |
Filing |
— |
| May 12, 2026 |
LBRX |
Quarterly results filed (8-K) |
Earnings |
— |
| May 12, 2026 |
TENX |
Quarterly results filed (8-K) |
Earnings |
— |
| May 12, 2026 |
IKT |
Quarterly results filed (8-K) |
Earnings |
— |
| May 12, 2026 |
IRD |
Quarterly results filed (8-K) |
Earnings |
— |
| May 12, 2026 |
OLMA |
Quarterly results filed (8-K) |
Earnings |
— |
| May 12, 2026 |
AVIR |
Quarterly results filed (8-K) |
Earnings |
— |
| May 12, 2026 |
PHVS |
6-K filed: Foreign issuer report |
Filing |
— |
| May 12, 2026 |
CRBP |
Quarterly results filed (8-K) |
Earnings |
— |
| May 12, 2026 |
IMNN |
Quarterly results filed (8-K) |
Earnings |
— |
| May 12, 2026 |
RLMD |
Quarterly results filed (8-K) |
Earnings |
— |
| May 12, 2026 |
IMTX |
6-K filed: Foreign issuer report |
Filing |
— |
| May 12, 2026 |
PRQR |
6-K filed: Foreign issuer report |
Filing |
— |
| May 12, 2026 |
PRQR |
6-K filed: Foreign issuer report |
Filing |
— |
| May 12, 2026 |
CAPR |
Quarterly results filed (8-K) |
Earnings |
— |
| May 12, 2026 |
SLS |
Quarterly results filed (8-K) |
Earnings |
— |
| May 12, 2026 |
KURA |
Quarterly results filed (8-K) |
Earnings |
— |
| May 12, 2026 |
KYTX |
Quarterly results filed (8-K) |
Earnings |
— |
| May 12, 2026 |
NGNE |
Quarterly results filed (8-K) |
Earnings |
— |
| May 12, 2026 |
SGMT |
Quarterly results filed (8-K) |
Earnings |
— |
| May 12, 2026 |
COYA |
8-K filed: Material agreement |
Corporate |
— |
| May 12, 2026 |
COYA |
Quarterly results filed (8-K) |
Earnings |
— |
| May 12, 2026 |
XFOR |
8-K filed: Leadership change |
Corporate |
— |
| May 12, 2026 |
ACHV |
Quarterly results filed (8-K) |
Earnings |
— |
| May 12, 2026 |
IMNM |
Quarterly results filed (8-K) |
Earnings |
— |
| May 12, 2026 |
MBRX |
8-K filed: Reg FD disclosure |
Filing |
— |
| May 12, 2026 |
ACIU |
6-K filed: Foreign issuer report |
Filing |
— |
| May 12, 2026 |
CLLS |
6-K filed: Foreign issuer report |
Filing |
— |
| May 12, 2026 |
CRIS |
Quarterly results filed (8-K) |
Earnings |
— |
| May 12, 2026 |
NKTX |
Quarterly results filed (8-K) |
Earnings |
— |
| May 12, 2026 |
MAZE |
Quarterly results filed (8-K) |
Earnings |
— |
| May 12, 2026 |
RIGL |
8-K filed: Material agreement |
Corporate |
— |
| May 13, 2026 |
AZN |
EPIC-ATTR: A Study to Evaluate the Effect of Eplontersen on the Transthyretin Reduction and Long-term Safety in Chinese Subjects With Transthyretin Amyloid Cardiomyopathy |
Trial Milestone |
Phase 3 |
| May 13, 2026 |
LLY |
A Study to Investigate the Efficacy and Safety of Lebrikizumab in Participants With Moderate-to-Severe Atopic Hand and Foot Dermatitis |
Trial Milestone |
Phase 3 |
| May 13, 2026 |
TAK |
6-K filed: Foreign issuer report |
Filing |
— |
| May 13, 2026 |
TAK |
6-K filed: Foreign issuer report |
Filing |
— |
| May 13, 2026 |
NVO |
6-K filed: Foreign issuer report |
Filing |
— |
| May 13, 2026 |
AAPG |
6-K filed: Foreign issuer report |
Filing |
— |
| May 13, 2026 |
ZBIO |
Quarterly results filed (8-K) |
Earnings |
— |
| May 13, 2026 |
ASND |
6-K filed: Foreign issuer report |
Filing |
— |
| May 13, 2026 |
CANF |
6-K filed: Foreign issuer report |
Filing |
— |
| May 13, 2026 |
PVLA |
8-K filed: Other event |
Filing |
— |
| May 13, 2026 |
TARA |
Quarterly results filed (8-K) |
Earnings |
— |
| May 13, 2026 |
CMPS |
Quarterly results filed (8-K) |
Earnings |
— |
| May 13, 2026 |
IMUX |
Quarterly results filed (8-K) |
Earnings |
— |
| May 13, 2026 |
TNGX |
Quarterly results filed (8-K) |
Earnings |
— |
| May 13, 2026 |
PBH |
Quarterly results filed (8-K) |
Earnings |
— |
| May 13, 2026 |
ELDN |
Quarterly results filed (8-K) |
Earnings |
— |
| May 13, 2026 |
TYRA |
Quarterly results filed (8-K) |
Earnings |
— |
| May 13, 2026 |
VTVT |
8-K filed: Other event |
Filing |
— |
| May 13, 2026 |
VTVT |
Quarterly results filed (8-K) |
Earnings |
— |
| May 13, 2026 |
ALT |
Quarterly results filed (8-K) |
Earnings |
— |
| May 13, 2026 |
ANRO |
8-K filed: Leadership change |
Corporate |
— |
| May 13, 2026 |
ANRO |
Quarterly results filed (8-K) |
Earnings |
— |
| May 13, 2026 |
ABEO |
Quarterly results filed (8-K) |
Earnings |
— |
| May 13, 2026 |
OMER |
Quarterly results filed (8-K) |
Earnings |
— |
| May 13, 2026 |
VALN |
6-K filed: Foreign issuer report |
Filing |
— |
| May 13, 2026 |
RVPH |
Quarterly results filed (8-K) |
Earnings |
— |
| May 13, 2026 |
RVPH |
8-K filed: Listing / standard notice, Other event |
Corporate |
— |
| May 13, 2026 |
XFOR |
8-K/A filed: Leadership change |
Corporate |
— |
| May 13, 2026 |
VRTX |
8-K filed: Leadership change |
Corporate |
— |
| May 13, 2026 |
BYSI |
Quarterly results filed (8-K) |
Earnings |
— |
| May 13, 2026 |
OTLK |
Quarterly results filed (8-K) |
Earnings |
— |
| May 13, 2026 |
MBRX |
8-K filed: Reg FD disclosure |
Filing |
— |
| May 13, 2026 |
SPRB |
Quarterly results filed (8-K) |
Earnings |
— |
| May 13, 2026 |
FATE |
Quarterly results filed (8-K) |
Earnings |
— |
| May 13, 2026 |
ACRV |
Quarterly results filed (8-K) |
Earnings |
— |
| May 13, 2026 |
PGEN |
Quarterly results filed (8-K) |
Earnings |
— |
| May 13, 2026 |
ALLO |
Quarterly results filed (8-K) |
Earnings |
— |
| May 14, 2026 |
AZN |
6-K filed: Foreign issuer report |
Filing |
— |
| May 14, 2026 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| May 14, 2026 |
JNJ |
A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer |
Trial Milestone |
Phase 1/Phase 2 |
| May 14, 2026 |
AMGN |
A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma |
Trial Milestone |
Phase 2 |
| May 14, 2026 |
BIIB |
8-K filed: Material agreement, Acquisition completed, Reg FD disclosure |
Corporate |
— |
| May 14, 2026 |
INBS |
Quarterly results filed (8-K) |
Earnings |
— |
| May 14, 2026 |
PRAX |
Double-blind, Randomized Trial of PRAX-628 in Adults With Focal Seizures to Evaluate Efficacy and Safety (POWER1) |
Trial Milestone |
Phase 2/Phase 3 |
| May 14, 2026 |
KPTI |
Quarterly results filed (8-K) |
Earnings |
— |
| May 14, 2026 |
EYPT |
8-K filed: Other event |
Filing |
— |
| May 14, 2026 |
OCGN |
8-K filed: Leadership change, Other event |
Corporate |
— |
| May 14, 2026 |
OCGN |
8-K filed: Reg FD disclosure |
Filing |
— |
| May 14, 2026 |
CABA |
Quarterly results filed (8-K) |
Earnings |
— |
| May 14, 2026 |
CABA |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| May 14, 2026 |
RGNX |
Quarterly results filed (8-K) |
Earnings |
— |
| May 14, 2026 |
CADL |
Quarterly results filed (8-K) |
Earnings |
— |
| May 14, 2026 |
MGTX |
Quarterly results filed (8-K) |
Earnings |
— |
| May 14, 2026 |
SGP |
Quarterly results filed (8-K) |
Earnings |
— |
| May 14, 2026 |
OCS |
6-K filed: Foreign issuer report |
Filing |
— |
| May 14, 2026 |
IVVD |
Quarterly results filed (8-K) |
Earnings |
— |
| May 14, 2026 |
CRBP |
8-K filed: Leadership change, Reg FD disclosure |
Corporate |
— |
| May 14, 2026 |
DCTH |
8-K filed: Leadership change |
Corporate |
— |
| May 14, 2026 |
ALMS |
Quarterly results filed (8-K) |
Earnings |
— |
| May 14, 2026 |
TLSA |
6-K filed: Foreign issuer report |
Filing |
— |
| May 14, 2026 |
CRVS |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| May 14, 2026 |
LRMR |
Quarterly results filed (8-K) |
Earnings |
— |
| May 14, 2026 |
CLRB |
Quarterly results filed (8-K) |
Earnings |
— |
| May 14, 2026 |
BFRI |
Quarterly results filed (8-K) |
Earnings |
— |
| May 14, 2026 |
RNXT |
Quarterly results filed (8-K) |
Earnings |
— |
| May 14, 2026 |
MPLT |
Quarterly results filed (8-K) |
Earnings |
— |
| May 14, 2026 |
CRMD |
Quarterly results filed (8-K) |
Earnings |
— |
| May 14, 2026 |
TPST |
Quarterly results filed (8-K) |
Earnings |
— |
| May 14, 2026 |
CRDL |
6-K filed: Foreign issuer report |
Filing |
— |
| May 14, 2026 |
EDIT |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| May 14, 2026 |
LTRN |
8-K filed: Material agreement, Other event |
Corporate |
— |
| May 14, 2026 |
GNPX |
8-K filed: Other event |
Filing |
— |
| May 15, 2026 |
ABBV |
A Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma |
Trial Milestone |
Phase 1/Phase 2 |
| May 15, 2026 |
ONC |
A First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in Participants With Advanced Solid Tumors |
Trial Milestone |
Phase 1 |
| May 15, 2026 |
ONC |
8-K filed: Other event |
Filing |
— |
| May 15, 2026 |
BNTX |
6-K filed: Foreign issuer report |
Filing |
— |
| May 15, 2026 |
IBRX |
Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma |
Trial Milestone |
Phase 1 |
| May 15, 2026 |
GRFS |
6-K filed: Foreign issuer report |
Filing |
— |
| May 15, 2026 |
CADL |
8-K filed: Reg FD disclosure |
Filing |
— |
| May 15, 2026 |
ANVS |
Quarterly results filed (8-K) |
Earnings |
— |
| May 15, 2026 |
PVLA |
8-K filed: Other event |
Filing |
— |
| May 15, 2026 |
NRIX |
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies |
Trial Milestone |
Phase 1 |
| May 15, 2026 |
IMRX |
Quarterly results filed (8-K) |
Earnings |
— |
| May 15, 2026 |
PROK |
Quarterly results filed (8-K) |
Earnings |
— |
| May 15, 2026 |
TRAW |
Quarterly results filed (8-K) |
Earnings |
— |
| May 15, 2026 |
NGEN |
6-K filed: Foreign issuer report |
Filing |
— |
| May 15, 2026 |
BCLI |
Quarterly results filed (8-K) |
Earnings |
— |
| May 15, 2026 |
ENSC |
Quarterly results filed (8-K) |
Earnings |
— |
| May 15, 2026 |
HURA |
Quarterly results filed (8-K) |
Earnings |
— |
| May 15, 2026 |
MBRX |
Quarterly results filed (8-K) |
Earnings |
— |
| May 15, 2026 |
ACIU |
6-K filed: Foreign issuer report |
Filing |
— |
| May 15, 2026 |
AGEN |
8-K filed: Leadership change |
Corporate |
— |
| May 15, 2026 |
CNSY |
Quarterly results filed (8-K) |
Earnings |
— |
| May 15, 2026 |
FTH |
Quarterly results filed (8-K) |
Earnings |
— |
| May 15, 2026 |
LTRN |
Quarterly results filed (8-K) |
Earnings |
— |
| May 15, 2026 |
WST |
RVU120 for Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms |
Trial Milestone |
Phase 2 |
| May 17, 2026 |
INCY |
A Study to Evaluate the Effect of Food on the Single-Dose Pharmacokinetics and a Drug-Drug Interaction Evaluation of Itraconazole and Carbamazepine on INCB123667 When Administered Orally to Healthy Adult Participants |
Trial Milestone |
Phase 1 |
| May 18, 2026 |
AZN |
6-K filed: Corporate announcement |
Corporate |
— |
| May 18, 2026 |
AZN |
6-K filed: Foreign issuer report |
Filing |
— |
| May 18, 2026 |
AZN |
6-K filed: Foreign issuer report |
Filing |
— |
| May 18, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| May 18, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| May 18, 2026 |
NVO |
6-K filed: Foreign issuer report |
Filing |
— |
| May 18, 2026 |
NBIX |
8-K filed: Material agreement, Acquisition completed, Reg FD disclosure |
Corporate |
— |
| May 18, 2026 |
RARE |
8-K filed: Leadership change |
Corporate |
— |
| May 18, 2026 |
IBRX |
8-K filed: Material agreement, Reg FD disclosure |
Corporate |
— |
| May 18, 2026 |
MIRM |
8-K filed: Material agreement, Other event |
Corporate |
— |
| May 18, 2026 |
BSX |
8-K filed: Other event |
Filing |
— |
| May 18, 2026 |
BSX |
8-K filed: Other event |
Filing |
— |
| May 18, 2026 |
CANF |
6-K filed: Foreign issuer report |
Filing |
— |
| May 18, 2026 |
CLRB |
8-K filed: Leadership change |
Corporate |
— |
| May 18, 2026 |
KYTX |
8-K filed: Leadership change, Other event |
Corporate |
— |
| May 18, 2026 |
TTRX |
8-K filed: Reg FD disclosure |
Filing |
— |
| May 18, 2026 |
NTHI |
Quarterly results filed (8-K) |
Earnings |
— |
| May 18, 2026 |
NGEN |
6-K filed: Foreign issuer report |
Filing |
— |
| May 18, 2026 |
WVE |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| May 18, 2026 |
LPCN |
8-K filed: Other event |
Filing |
— |
| May 18, 2026 |
OTLK |
Quarterly results filed (8-K) |
Earnings |
— |
| May 18, 2026 |
GOSS |
Quarterly results filed (8-K) |
Earnings |
— |
| May 18, 2026 |
CGEM |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| May 18, 2026 |
SXTP |
8-K filed: Leadership change |
Corporate |
— |
| May 19, 2026 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| May 19, 2026 |
AMGN |
8-K filed: Leadership change |
Corporate |
— |
| May 19, 2026 |
TAK |
6-K filed: Foreign issuer report |
Filing |
— |
| May 19, 2026 |
DFTX |
8-K filed: Other event |
Filing |
— |
| May 19, 2026 |
VTGN |
8-K filed: Leadership change, Reg FD disclosure |
Corporate |
— |
| May 19, 2026 |
IMUX |
8-K filed: Leadership change, Reg FD disclosure |
Corporate |
— |
| May 19, 2026 |
TLSA |
6-K filed: Foreign issuer report |
Filing |
— |
| May 19, 2026 |
RLAY |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| May 19, 2026 |
TTRX |
8-K filed: Reg FD disclosure |
Filing |
— |
| May 19, 2026 |
BLRX |
6-K filed: Foreign issuer report |
Filing |
— |
| May 19, 2026 |
OKYO |
6-K filed: Foreign issuer report |
Filing |
— |
| May 19, 2026 |
TRDA |
8-K filed: Reg FD disclosure |
Filing |
— |
| May 19, 2026 |
LPCN |
8-K filed: Other event |
Filing |
— |
| May 20, 2026 |
LLY |
8-K filed: Other event |
Filing |
— |
| May 20, 2026 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| May 20, 2026 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| May 20, 2026 |
GILD |
8-K filed: Material agreement, Other event |
Corporate |
— |
| May 20, 2026 |
ALKS |
8-K filed: Leadership change |
Corporate |
— |
| May 20, 2026 |
DFTX |
A Phase 3 Trial of DT120 for Major Depressive Disorder (Emerge) |
Trial Milestone |
Phase 3 |
| May 20, 2026 |
IMVT |
Quarterly results filed (8-K) |
Earnings |
— |
| May 20, 2026 |
ANVS |
8-K filed: Material agreement, Reg FD disclosure |
Corporate |
— |
| May 20, 2026 |
PVLA |
8-K filed: Other event |
Filing |
— |
| May 20, 2026 |
BLTE |
6-K filed: Foreign issuer report |
Filing |
— |
| May 20, 2026 |
ABVX |
6-K filed: Foreign issuer report |
Filing |
— |
| May 20, 2026 |
CLLS |
6-K filed: Foreign issuer report |
Filing |
— |
| May 20, 2026 |
DRUG |
6-K filed: Foreign issuer report |
Filing |
— |
| May 20, 2026 |
RIGL |
8-K filed: Leadership change |
Corporate |
— |
| May 21, 2026 |
SVA |
6-K filed: Foreign issuer report |
Filing |
— |
| May 21, 2026 |
TVTX |
8-K filed: Leadership change |
Corporate |
— |
| May 21, 2026 |
BCYC |
8-K filed: Other event |
Filing |
— |
| May 21, 2026 |
OLMA |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| May 21, 2026 |
CRBP |
8-K filed: Material agreement, Leadership change, Reg FD disclosure |
Corporate |
— |
| May 21, 2026 |
TLSA |
6-K filed: Foreign issuer report |
Filing |
— |
| May 21, 2026 |
RLAY |
8-K filed: Material agreement |
Corporate |
— |
| May 21, 2026 |
BCAX |
8-K filed: Other event |
Filing |
— |
| May 21, 2026 |
MCUJF |
6-K filed: Foreign issuer report |
Filing |
— |
| May 21, 2026 |
MCUJF |
6-K filed: Foreign issuer report |
Filing |
— |
| May 21, 2026 |
MCUJF |
6-K filed: Foreign issuer report |
Filing |
— |
| May 21, 2026 |
COAG |
Quarterly results filed (8-K) |
Earnings |
— |
| May 21, 2026 |
CLLS |
6-K filed: Foreign issuer report |
Filing |
— |
| May 21, 2026 |
FTH |
8-K filed: Other event |
Filing |
— |
| May 21, 2026 |
BDTX |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| May 22, 2026 |
MRK |
8-K filed: Other event |
Filing |
— |
| May 22, 2026 |
GSK |
Results filed (6-K) |
Earnings |
— |
| May 22, 2026 |
NVO |
6-K filed: Foreign issuer report |
Filing |
— |
| May 22, 2026 |
NVO |
6-K filed: Foreign issuer report |
Filing |
— |
| May 22, 2026 |
BNTX |
6-K filed: Foreign issuer report |
Filing |
— |
| May 22, 2026 |
AAPG |
6-K filed: Foreign issuer report |
Filing |
— |
| May 22, 2026 |
KPTI |
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma |
Trial Milestone |
Phase 3 |
| May 22, 2026 |
PHAR |
6-K filed: Foreign issuer report |
Filing |
— |
| May 22, 2026 |
DNLI |
8-K filed: Reg FD disclosure |
Filing |
— |
| May 22, 2026 |
ABVX |
6-K filed: Foreign issuer report |
Filing |
— |
| May 22, 2026 |
ONCY |
8-K filed: Other event |
Filing |
— |
| May 22, 2026 |
CATX |
8-K filed: Other event |
Filing |
— |
| May 22, 2026 |
NGEN |
6-K filed: Foreign issuer report |
Filing |
— |
| May 22, 2026 |
BLRX |
6-K filed: Foreign issuer report |
Filing |
— |
| May 22, 2026 |
TPST |
8-K filed: Listing / standard notice |
Corporate |
— |
| May 22, 2026 |
TPST |
8-K filed: Leadership change |
Corporate |
— |
| May 22, 2026 |
ENSC |
8-K filed: Listing / standard notice |
Corporate |
— |
| May 22, 2026 |
MBRX |
8-K filed: Reg FD disclosure |
Filing |
— |
| May 22, 2026 |
FTH |
8-K filed: Other event |
Filing |
— |
| May 22, 2026 |
MAZE |
8-K filed: Leadership change |
Corporate |
— |
| May 23, 2026 |
ONC |
Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies |
Trial Milestone |
Phase 3 |
| May 25, 2026 |
JNJ |
A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis |
Trial Milestone |
Phase 3 |
| May 25, 2026 |
MRNA |
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated Mothers |
Trial Milestone |
Phase 2 |
| May 26, 2026 |
AZN |
6-K filed: Foreign issuer report |
Filing |
— |
| May 26, 2026 |
AZN |
6-K filed: Foreign issuer report |
Filing |
— |
| May 26, 2026 |
AZN |
6-K filed: Foreign issuer report |
Filing |
— |
| May 26, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| May 26, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| May 26, 2026 |
TAK |
6-K filed: Foreign issuer report |
Filing |
— |
| May 26, 2026 |
TAK |
6-K filed: Foreign issuer report |
Filing |
— |
| May 26, 2026 |
TAK |
6-K filed: Foreign issuer report |
Filing |
— |
| May 26, 2026 |
TAK |
6-K filed: Foreign issuer report |
Filing |
— |
| May 26, 2026 |
TAK |
6-K filed: Foreign issuer report |
Filing |
— |
| May 26, 2026 |
KLRA |
Quarterly results filed (8-K) |
Earnings |
— |
| May 26, 2026 |
CGON |
8-K filed: Leadership change |
Corporate |
— |
| May 26, 2026 |
RNAC |
8-K filed: Material agreement, Leadership change, Reg FD disclosure |
Corporate |
— |
| May 26, 2026 |
AWHL |
8-K filed: Material agreement |
Corporate |
— |
| May 26, 2026 |
OLMA |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| May 26, 2026 |
CRBP |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| May 26, 2026 |
KNSA |
8-K filed: Material agreement |
Corporate |
— |
| May 26, 2026 |
TRAW |
8-K filed: Other event |
Filing |
— |
| May 26, 2026 |
NGEN |
6-K filed: Foreign issuer report |
Filing |
— |
| May 26, 2026 |
LPCN |
8-K filed: Other event |
Filing |
— |
| May 26, 2026 |
OTLK |
8-K filed: Other event |
Filing |
— |
| May 26, 2026 |
CRDL |
6-K filed: Foreign issuer report |
Filing |
— |
| May 26, 2026 |
MBRX |
8-K filed: Reg FD disclosure |
Filing |
— |
| May 26, 2026 |
EDIT |
8-K filed: Material agreement, Other event |
Corporate |
— |
| May 26, 2026 |
EDIT |
8-K filed: Other event |
Filing |
— |
| May 26, 2026 |
EDIT |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| May 26, 2026 |
GNPX |
8-K filed: Other event |
Filing |
— |
| May 27, 2026 |
AZN |
6-K filed: Clinical or regulatory announcement |
Filing |
— |
| May 27, 2026 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| May 27, 2026 |
SNY |
6-K filed: Foreign issuer report |
Filing |
— |
| May 27, 2026 |
NVO |
6-K filed: Foreign issuer report |
Filing |
— |
| May 27, 2026 |
ALNY |
8-K filed: Leadership change |
Corporate |
— |
| May 27, 2026 |
TGTX |
8-K filed: Other event |
Filing |
— |
| May 27, 2026 |
IMUX |
8-K filed: Leadership change, Reg FD disclosure |
Corporate |
— |
| May 27, 2026 |
MDWD |
6-K filed: Foreign issuer report |
Filing |
— |
| May 27, 2026 |
GERN |
8-K filed: Leadership change |
Corporate |
— |
| May 27, 2026 |
TRAW |
8-K filed: Reg FD disclosure |
Filing |
— |
| May 27, 2026 |
TTRX |
8-K filed: Reg FD disclosure |
Filing |
— |
| May 27, 2026 |
NERV |
8-K filed: Material agreement, Other event |
Corporate |
— |
| May 27, 2026 |
BLRX |
6-K filed: Foreign issuer report |
Filing |
— |
| May 27, 2026 |
LKFT |
A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin Lymphoma |
Trial Milestone |
Phase 1/Phase 2 |
| May 27, 2026 |
LKFT |
6-K filed: Foreign issuer report |
Filing |
— |
| May 27, 2026 |
QTTB |
8-K filed: Material agreement, Other event |
Corporate |
— |
| May 28, 2026 |
GSK |
6-K filed: Clinical or regulatory announcement |
Filing |
— |
| May 28, 2026 |
IONS |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| May 28, 2026 |
NBIX |
8-K filed: Leadership change |
Corporate |
— |
| May 28, 2026 |
AAPG |
6-K filed: Foreign issuer report |
Filing |
— |
| May 28, 2026 |
AAPG |
6-K filed: Foreign issuer report |
Filing |
— |
| May 28, 2026 |
KPTI |
8-K filed: Leadership change |
Corporate |
— |
| May 28, 2026 |
PHAR |
6-K filed: Foreign issuer report |
Filing |
— |
| May 28, 2026 |
VIR |
8-K filed: Leadership change |
Corporate |
— |
| May 28, 2026 |
MLTX |
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug |
Trial Milestone |
Phase 3 |
| May 28, 2026 |
CANF |
6-K filed: Foreign issuer report |
Filing |
— |
| May 28, 2026 |
CORT |
8-K filed: Leadership change |
Corporate |
— |
| May 28, 2026 |
IMUX |
8-K filed: Reg FD disclosure |
Filing |
— |
| May 28, 2026 |
TLSA |
6-K filed: Foreign issuer report |
Filing |
— |
| May 28, 2026 |
ANRO |
8-K filed: Leadership change |
Corporate |
— |
| May 28, 2026 |
BCLI |
8-K filed: Leadership change, Reg FD disclosure |
Corporate |
— |
| May 28, 2026 |
OTLK |
8-K filed: Other event |
Filing |
— |
| May 28, 2026 |
MNKD |
8-K filed: Other event |
Filing |
— |
| May 28, 2026 |
DRUG |
6-K filed: Foreign issuer report |
Filing |
— |
| May 28, 2026 |
ALLO |
8-K filed: Leadership change |
Corporate |
— |
| May 29, 2026 |
AZN |
6-K filed: Foreign issuer report |
Filing |
— |
| May 29, 2026 |
INCY |
Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy. |
Trial Milestone |
Phase 2 |
| May 29, 2026 |
SVA |
6-K filed: Foreign issuer report |
Filing |
— |
| May 29, 2026 |
EXEL |
8-K filed: Leadership change |
Corporate |
— |
| May 29, 2026 |
JAZZ |
8-K filed: Leadership change |
Corporate |
— |
| May 29, 2026 |
ACAD |
8-K filed: Leadership change |
Corporate |
— |
| May 29, 2026 |
REPL |
8-K filed: Reg FD disclosure |
Filing |
— |
| May 29, 2026 |
ATNM |
8-K filed: Listing / standard notice, Reg FD disclosure |
Corporate |
— |
| May 29, 2026 |
KYTX |
KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis |
Trial Milestone |
Phase 1/Phase 2 |
| May 29, 2026 |
SYRE |
8-K filed: Leadership change |
Corporate |
— |
| May 29, 2026 |
TPST |
8-K filed: Leadership change |
Corporate |
— |
| May 29, 2026 |
OTLK |
8-K filed: Other event |
Filing |
— |
| May 29, 2026 |
MBRX |
8-K filed: Reg FD disclosure |
Filing |
— |
| May 31, 2026 |
SVA |
Study to Evaluate the Safety and Immunogenicity of a Lyophilized Herpes Zoster Virus mRNA Vaccine |
Trial Milestone |
Phase 1/Phase 2 |
| May 31, 2026 |
AAPG |
A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL |
Trial Milestone |
Phase 2 |
| May 31, 2026 |
IBRX |
QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors |
Trial Milestone |
Phase 1 |
| May 31, 2026 |
HURA |
IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC) |
Trial Milestone |
Phase 1 |